Physician profile
Michael Alan Wood
NPI 1801866363
$58,968.96
in general payments reported to CMS, 2019-2025
37 companies · $47K in 2025
The $47K reported for 2025 was more than what 97% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $1,036 · 2021: $97.08 · 2022: $380 · 2023: $6,978 · 2024: $2,962 · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Travel and Lodging: $3,861 · Food and Beverage: $2,821 · Consulting Fee: $1,575 · Education: $74.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,117.50 |
| Travel and Lodging | $3,861.13 |
| Food and Beverage | $2,821.33 |
| Consulting Fee | $1,575.00 |
| Education | $74.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $28,826.49 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $18,443.90 | 2023-2025 | Strensiq |
| Lilly USA, LLC | $5,238.73 | 2019-2023 | Lyumjev |
| Mannkind Corporation | $2,685.35 | 2020-2025 | Afrezza |
| Novo Nordisk INC | $623.40 | 2019-2025 | Sogroya, Wegovy, Rybelsus |
| Ascensia Diabetes Care US INC. | $491.15 | 2020-2024 | |
| Tandem Diabetes Care, INC. | $454.97 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $256.68 | 2019-2025 | |
| Tolmar, INC. | $224.93 | 2024-2025 | Fensolvi |
| Medtronic, INC. | $207.81 | 2022-2025 | Minimed 780g, Minimed 770g |
| Beta Bionics, INC. | $196.79 | 2024 | Ilet Bionic Pancreas |
| Inari Medical, INC. | $167.50 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amarin Pharma, INC. | $136.24 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $117.66 | 2022 | |
| Insulet Corporation | $93.37 | 2019-2025 | Omnipod |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $89.70 | 2022-2024 | |
| Amphastar Pharmaceuticals, INC. | $61.29 | 2024-2025 | |
| Eton Pharmaceuticals, INC. | $60.75 | 2023-2025 | Alkindi, Increlex, Khindivi |
| Sequel Med Tech, LLC | $58.99 | 2025 | Twiist |
| Azurity Pharmaceuticals, INC. | $58.19 | 2023 | Triptodur |
| Covidien Lp | $55.27 | 2019 | |
| Amneal Pharmaceuticals LLC | $44.28 | 2019-2020 | |
| Rhythm Pharmaceuticals, INC. | $41.85 | 2025 | Imcivree |
| Abbott Laboratories | $40.27 | 2023-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $39.23 | 2023-2024 | Dexcom G6 Transmitter |
| Embecta Corp. | $34.46 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Abbvie INC. | $33.21 | 2023-2025 | Lupron Depot |
| Zealand Pharma US, INC. | $32.19 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $25.71 | 2022 | |
| Endo Pharmaceuticals INC. | $22.56 | 2021 | |
| Xeris Pharmaceuticals, INC. | $21.07 | 2022 | |
| Lifescan, INC. | $20.60 | 2023 | |
| Biomarin Pharmaceutical INC. | $18.27 | 2022 | |
| Horizon Therapeutics Plc | $16.38 | 2020 | |
| Amryt Pharma Holdings Ltd | $15.57 | 2021 | |
| Ibsa Pharma INC. | $14.15 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.